Johnson & Johnson (JNJ) Construction in Progress (2010 - 2021)
Johnson & Johnson recorded quarterly Construction in Progress of $4.3 billion in Q1 2021, up 18.67% quarter-over-quarter from $3.6 billion in Q4 2019, and up 18.67% year-over-year from $3.6 billion in Q1 2020.
Johnson & Johnson's Construction in Progress history runs 10 years deep, the most recent figure standing at $4.3 billion for Q1 2021.
- In Q1 2021, Construction in Progress rose 18.67% year-over-year to $4.3 billion; the TTM figure through Jan 2021 stood at $4.3 billion (up 18.67% YoY), while the FY2021 annual figure was $4.3 billion, up 18.67% from the prior year.
- Construction in Progress came in at $4.3 billion for Q1 2021 at Johnson & Johnson, up from $3.6 billion in the prior quarter.
- In the past five years, Construction in Progress ranged from a high of $4.3 billion in Q1 2021 to a low of $3.4 billion in Q1 2017.
- A 4-year average of $3.7 billion and a median of $3.6 billion in 2019 frame the typical range for Construction in Progress.
- Across the five-year window, Construction in Progress dropped 6.17% in 2019 and gained 18.67% in 2021, its largest moves.
- Johnson & Johnson's Construction in Progress stood at $3.4 billion in 2017, then advanced by 12.41% to $3.9 billion in 2018, then decreased by 6.17% to $3.6 billion in 2019, then climbed by 18.67% to $4.3 billion in 2021.
- According to Business Quant data, Construction in Progress over the past three periods registered $4.3 billion, $3.6 billion, and $3.9 billion for Q1 2021, Q4 2019, and Q4 2018 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Construction in Progress (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | - |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | - |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | - |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | - |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | 1.54 Bn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jan 3, 2021 | 4.32 Bn |
| Dec 29, 2019 | 3.64 Bn |
| Dec 30, 2018 | 3.88 Bn |
| Dec 31, 2017 | 3.45 Bn |
| Jan 1, 2017 | 3.35 Bn |
| Jan 3, 2016 | 3.53 Bn |
| Dec 28, 2014 | 3.60 Bn |
| Dec 29, 2013 | 3.30 Bn |
| Dec 30, 2012 | 2.74 Bn |
| Jan 1, 2012 | 2.50 Bn |
| Jan 2, 2011 | 2.58 Bn |
| Jan 3, 2010 | 2.52 Bn |